Safety of Combining Desvenlafaxine with Lithium

Potential Interactions and Risks

• Desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), increases serotonin and norepinephrine levels in the brain, and when combined with lithium, a serotonergic drug, there is a risk of serotonin syndrome, a potentially serious condition, according to the American Academy of Child and Adolescent Psychiatry 1, 2, 3, 4.
• Serotonin syndrome symptoms can develop within 24-48 hours after combining medications and include mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity, which can be life-threatening 3, 4.

Monitoring and Management Recommendations

• The American Academy of Child and Adolescent Psychiatry recommends starting with lower doses and increasing slowly while monitoring for symptoms of serotonin syndrome, especially in the first 24-48 hours after dosage changes 3.
• Regular monitoring should include vital signs and mental status assessment, and evaluation for neuromuscular symptoms, as recommended by the American Academy of Child and Adolescent Psychiatry 4.
• Lithium requires regular blood level monitoring due to its narrow therapeutic window, as stated by Clinical Gastroenterology and Hepatology 5.
• If signs of serotonin syndrome develop, both medications should be discontinued immediately and hospital-based treatment with supportive care and continuous cardiac monitoring should be initiated, according to the American Academy of Child and Adolescent Psychiatry 4.